Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.69 |
| ▸ | EGFR | P00533 | 4/20 | 0.69 |
| ▸ | CSK | P41240 | 2/20 | 0.69 |
| ▸ | IGF1R | P08069 | 1/20 | 0.69 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.69 |
| ▸ | SRC | P12931 | 1/20 | 0.69 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.69 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.69 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.69 |
| ▸ | CDK2 | P24941 | 1/20 | 0.69 |
| ▸ | JAK3 | P52333 | 1/20 | 0.69 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.69 |
| ▸ | AURKA | O14965 | 15/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.49 |
| ▸ | FLT1 | P17948 | 2/20 | 0.49 |
| ▸ | FLT4 | P35916 | 2/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5048903 | 0.91 | AURKB (0.80) | KDRAURKBEGFRCSKIGF1R | |
| SCHEMBL5049536 | 0.91 | KDR (0.67) | KDRAURKBEGFRCSKIGF1R | |
| SCHEMBL5046812 | 0.90 | AURKB (0.85) | KDRAURKBEGFRCSKIGF1R | |
| SCHEMBL3891880 | 0.86 | KDR (0.68) | KDRAURKBEGFRCSKIGF1R | |
| SCHEMBL5045694 | 0.85 | KDR (0.62) | KDRAURKBEGFRCSKIGF1R | |
| SCHEMBL5045057 | 0.83 | AURKA (0.66) | KDRAURKBEGFRCSKIGF1R | |
| SCHEMBL5048650 | 0.82 | AURKB (0.72) | KDRAURKBEGFRCSKIGF1R | |
| SCHEMBL5045267 | 0.82 | AURKB (0.91) | KDRAURKBEGFRCSKIGF1R | |
| SCHEMBL5045154 | 0.82 | AURKB (1.00) | KDRAURKBEGFRCSKIGF1R | |
| SCHEMBL31060166 | 0.82 | AURKB (1.00) | KDRAURKBEGFRCSKIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407946-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| US-20060058523-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1575946-A1 | QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004058752-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058523-A1 | Quinazoline compounds | NDUFS5, ABL1, NDUFS7 | KDR 2844/4885AURKB 735/4885EGFR 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.